Oncology Clinical Briefing: Expert Insights for Managing Bladder Cancer in the Time of COVID-19

As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients. It will also evaluate responsive institutional and clinical protocols that are effective in simultaneously mitigating COVID-19 transmission and optimizing cancer care. Lastly, experts on the front lines will discuss forward-thinking strategies oncology clinicians can employ to outpace the pandemic and provide uninterrupted, high-quality care for patients. 

Target Audience

This online educational activity is targeted to urologists, urologic oncologists, medical oncologists, surgical oncologists, radiation oncologists, and primary care physicians.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Review the evolving epidemiology of the novel coronavirus (SARS-CoV-2) outbreak, and identify key infection risk considerations for clinicians managing patients with bladder cancer.
  • Evaluate adaptive institutional and clinical protocols for mitigating transmission of COVID-19 while maintaining high integrity cancer care.
  • Discuss forward-thinking strategies oncology clinicians can employ to “stay ahead” of the pandemic and optimize outcomes for their patients.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Course opens: 
Course expires: 

Arjun Balar, MD
Director, Genitourinary Medical Oncology Program
NYU Langone Perlmutter Cancer Center
New York, New York

Dr. Balar is an Associate Professor of Medicine and the Director of the Genitourinary Medical Oncology Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center in New York, New York. Dr. Balar received his Medical Degree from the University of South Florida–Morsani College of Medicine in Tampa, Florida, as a member of the Alpha-Omega-Alpha Honor Medical Society. He completed his Internal Medicine residency at New York-Presbyterian–Weill Cornell Medical Center in New York, New York, and went on to complete a fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center in New York, New York, where he focused his research efforts entirely on novel therapies in muscle-invasive and metastatic bladder cancer.
Dr. Balar has focused primarily on cisplatin-ineligible patients with the goal of identifying better tolerated and more effective therapies in advanced and invasive/high-grade urothelial cancer, with a particular focus on novel immunotherapies and combinations.


Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia School of Medicine
Charlottesville, Virginia


Dr. Dreicer is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. He serves as Section Head of Medical Oncology and Co-Director of the Paul Mellon Urologic Cancer Institute. He is a Professor of Medicine and Urology at the University of Virginia School of Medicine in Charlottesville, Virginia. Dr. Dreicer previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center in Cleveland, Ohio. He is Board Certified in Internal Medicine and Medical Oncology. His areas of specialization are the management of genitourinary malignancies, and the design and conduct of clinical trials in urologic oncology.

Dr. Dreicer received his BS Degree at Colorado State University and his MS Degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his Medical Degree from the University of Texas Medical School in Houston, Texas. He completed an Internal Medicine residency at Indiana University in Indianapolis, Indiana, followed by a Medical Oncology Fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin. Dr. Dreicer has published widely in genitourinary oncology and served as Principal Investigator in a large number of studies in genitourinary neoplasms. He previously served as Co-Chair of the National Cancer Institute Genitourinary Cancers Steering Committee and is a member of the editorial board of the <em> New England Journal of Medicine’s Journal Watch Hematology and Oncology <em>. In October 2016, he was awarded Mastership in the American College of Physicians.


Ashish Kamat, MD, MBBS, FACS 
University of Texas, MD Anderson Cancer Center
Houston, Texas


Dr. Kamat is a Professor of Urologic Oncology and Wayne B. Duddlesten Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. He is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, organ sparing and minimally invasive techniques. Dr. Kamat maintains an active research portfolio in this area with a focus on developing novel therapies, and identifying predictors of response to therapy (eg, intravesical immunotherapy), as a first step toward personalized cancer therapeutics. He has initiated, led, and been active in several large studies, including multinational trials in bladder cancer with findings published in high-impact journals.  

Dr. Kamat is listed in ‘Who’s Who in Medicine’ and ‘Best Doctors in America’ and has won the ‘Compassionate Doctor Award’ from patient groups. He is President of the International Bladder Cancer Group and President of the International Bladder Cancer Network. He is also Associate Editor, <em>European Urology Oncology</em> and Associate Cancer Center Director, RFHNH, Mumbai, India.

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity. Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations.

A commercial interest is defined as any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


Bryan C. Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.


Arjun V. Balar, MD—has disclosed that he is a consultant for AstraZeneca, Genentech, Merck, Pfizer, and Roche. He also receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.

Robert Dreicer, MD, MS, MACP, FASCO—has disclosed that he is a consultant for Astellas, Eisai, Janssen, Orion, Novartis, Pfizer, Seattle Genetics, and Vizuri. He also receives grant/research support from Exelixis, Merck, Roche, and Seattle Genetics.

Ashish M. Kamat, MD, MBBS, FACS—has disclosed that he is a consultant for Abbott Molecular, Arquer, Asieris, AstraZeneca, BioClin Therapeutics, Bristol-Myers Squibb, Cepheid, Cold Genesys, Eisai, Ferring, FKD Industries, Imagin, MDxHealth, Medac, Merck, Pfizer, Photocure, Roviant, Sesen Bio, Theralase, TMC Innovation, and US Biotest. He also receives grant/research support from Bristol-Myers Squibb, FKD Industries, Merck, and Photocure.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Please login or register to take this course.